Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation

L Bonaccorsi, S Marchiani, M Muratori, G Forti… - Journal of cancer …, 2004 - Springer
Purpose Androgen-independent prostate cancer (AI-PC) is characterized by a higher
invasive potential compared to hormone-responsive prostate cancer. A therapeutic option …

Signaling mechanisms that mediate invasion in prostate cancer cells

L Bonaccorsi, S Marchiani, M Muratori… - Annals of the New …, 2004 - Wiley Online Library
Recent evidence indicates that androgen‐sensitive prostate cancer cells have a less
malignant phenotype characterized by reduced migration and invasion. We investigated …

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice

A Angelucci, GL Gravina, N Rucci… - Endocrine-related …, 2006 - erc.bioscientifica.com
The activation of epidermal growth factor receptor (EGF-R) plays a key role in the promotion
of proliferation and invasion in prostatic carcinoma (PCa). Gefitinib (Iressa; ZD1839), an …

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen‐sensitive prostate cancer cells by an interaction between EGFR and androgen receptor …

L Bonaccorsi, V Carloni, M Muratori… - … Journal of Cancer, 2004 - Wiley Online Library
We previously demonstrated that expression of androgen receptor (AR) by transfection of
the androgen‐independent prostate cancer cell line PC3 decreases invasion and adhesion …

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

W Qi, LS Cooke, A Stejskal, C Riley, KD Croce… - BMC cancer, 2009 - Springer
Background Prostate cancer is a common disease in men and at present there is no
effective therapy available due to its recurrence despite androgen deprivation therapy. The …

Targeting of EGFR tyrosine kinase by ZD1839 (“Iressa”) in androgen-responsive prostate cancer in vitro

I Bellezza, S Bracarda, C Caserta, A Minelli - Molecular genetics and …, 2006 - Elsevier
EGFR, highly expressed in a variety of human malignancies, is correlated with poor tumour
differentiation, high tumour growth and metastatic rate. EGF and several other ligands, such …

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary …

C Vicentini, C Festuccia, GL Gravina… - Journal of cancer …, 2003 - Springer
Purpose. To investigate the effects of the epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) ZD1839 ('Iressa') on the cellular proliferation of androgen-sensitive and …

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines

C Festuccia, P Muzi, D Millimaggi… - Endocrine-related …, 2005 - erc.bioscientifica.com
To date, no effective therapeutic treatment allows abrogation of the progression of prostate
cancer (PCa) to more invasive forms. One of the major targets for the therapy in PCa can be …

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

Y Gan, C Shi, L Inge, M Hibner, J Balducci, Y Huang - Oncogene, 2010 - nature.com
Upregulation of epidermal growth factor receptor (EGFR) and subsequent increases in
extracellular-regulated kinase (ERK) and Akt signaling are implicated in prostate cancer …

The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines

A Ünlü, RE Leake - The International journal of biological …, 2003 - journals.sagepub.com
Increased urokinase plasminogen activator (uPA) levels and epidermal growth factor
receptor (EGFR)-related tyrosine kinase activity are associated with poor prognosis in …